Association of GDF15, NTpoBNP and PLGF with subclinical cardiac dysfunction in type 2 diabetes: effects of novel antidiabetic treatment.

25 August 2023 (13:15 - 14:00)

Organised by:

Video

Sign in for access options

Abstract

Slides

About the speaker

Doctor Ignatios Ikonomidis

National & Kapodistrian University of Athens, Athens (Greece)

6 More presentations in this session

Presentation thumbnail

Effect of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors and their combination on markers of neurohumoral activation and left atrial strain.

Doctor I. Ikonomidis (Athens, GR)

Abstract Slides Video

Presentation thumbnail

Cardioprotective pharmacotherapy in patients with type 2 diabetes across the Middle East and Africa: the PACT-MEA study

Professor S. Verma (Toronto, CA)

Abstract Slides

Presentation thumbnail

Incident cardiovascular disease in women with type 1 or type 2 diabetes by history of hypertensive disorders of pregnancy

Associate Professor S. Timpka (Malmo, SE)

Abstract Slides Video

Presentation thumbnail

Change in hbA1c following treatment with and the short-term risk of major adverse cardiovascular outcomes

Mrs B. Zareini (Copenhagen, DK)

Abstract Slides Video

Presentation thumbnail

The prognostic value of high-sensitivity cardiac troponin t in diabetes patients without coronary artery disease

Mr Y. He (Guangzhou, CN)

Abstract Slides Video

Access the full session

Session thumbnail

Diabetes and the heart (1)

The Event

Event poster

ESC Congress 2023

25 August 2023 13:15 CET

You may be interested in

Congress Presentation

Effect of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors and their combination on markers of neurohumoral activation and left atrial strain.

Congress Presentation

Effects of glucagon-like peptide-1 receptor agonists, sodium-glucose cotransporter-2 inhibitors and their combination on mitochondrial-derived peptide-c and on markers of neurohumoral activation

Congress Presentation

Effect of semaglutide on global longitudinal strain and global myocardial work efficiency in patients with uncontrolled type 2 diabetes mellitus and obesity.